Cargando…
Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
Central diabetes insipidus (CDI) is a rare endocrine disease deriving from an insufficient production or secretion of anti-diuretic hormone. Recently, CDI has been reported as a rare side effect triggered by immune checkpoint inhibitors (ICI) in cancer patients. Despite its current rarity, CDI trigg...
Autores principales: | Barnabei, Agnese, Strigari, Lidia, Corsello, Andrea, Paragliola, Rosa Maria, Iannantuono, Giovanni Maria, Salvatori, Roberto, Corsello, Salvatore Maria, Torino, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978963/ https://www.ncbi.nlm.nih.gov/pubmed/35388297 http://dx.doi.org/10.3389/fendo.2022.840971 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?
por: Barnabei, Agnese, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
por: Barnabei, Agnese, et al.
Publicado: (2022) -
Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2023) -
Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients
por: Delle Cese, Francesca, et al.
Publicado: (2021) -
Treating Hypopituitarism in the Over 65s: Review of Clinical Studies
por: Paragliola, Rosa Maria, et al.
Publicado: (2023)